The Plasma Fractionation Market is projected to grow at a CAGR of 7% during the forecast period 2021-2028.
More on YorkPedia:
- Bringing the Authentic Music of R&B the Recertified Teenager Releases New Track ‘The Groove’
- The North Carolina Music Band Apollo Craven Is Spreading Its Charm with Their Soundtracks
- Learn How to Measure Press Release Success in 11 Simple Ways
- Stay Updated about the International Music Industry with Daily Music Roll’s Music News
- Get Nostalgic with the Album ‘To Love Somebody…’ by O’Neill Fernandes
(YorkPedia Editorial):- Cranston, Rhode Island Nov 9, 2021 (Issuewire.com) – Market Overview
Plasma fractionation is a method of separating various components of blood plasma to treat protein deficiency in individuals and also in industrial applications as packaging material. It is used in the prevention and treatment of life-threatening diseases caused by trauma, immunologic disorders, and infections.
Download free sample: https://www.datamintelligence.com/download-sample/plasma-fractionation-market
The rising prevalence of respiratory diseases and alpha-1 antitrypsin deficiency (ATTD) along with the growing geriatric population, increasing use of immunoglobulins in various therapeutic applications are some of the factors driving the growth of the plasma fractionation market.
Alpha-1 Antitrypsin (AAT) is a protein made in the liver in healthy humans, and certain genetic defects diminish or eliminate the liver’s ability to make AAT. An AAT deficiency causes a variety of conditions, including emphysema, neonatal hepatitis, jaundice, and chronic obstructive pulmonary disease (COPD). Alpha1-antitrypsin deficiency (AATD) is one of the most common genetic disorders associated with significant morbidity and mortality. The prevalence of diagnosed AATD increases with age. According to the European Respiratory Journal, 2017, it is estimated that the number of diagnosed AATD patients in Germany was 19162, of whom an estimated 8684 patients would have had an additional pulmonary diagnosis. The prevalence of COPD and emphysema in AATD was 32% and 21%, respectively. In addition, according to the WHO, Respiratory diseases are the leading causes of death and disability in the world. About 65 million people suffer from the chronic obstructive pulmonary disease (COPD) and 3 million die from it each year, making it the third leading cause of death worldwide. About 334 million people suffer from asthma, the most common chronic disease of childhood affecting 14% of all children globally. Hence, the rising prevalence of various respiratory diseases and Alpha1-antitrypsin deficiency (AATD) is driving the growth of the plasma fractionation market globally.
Various advancements in the product by major manufacturers is also one of the major factor contributing to the growth of the market. For instance, in June 2019, Grifols, launched the VISTASEAL fibrin sealant with Ethicon Inc. as part of a broad global relationship to provide plasma-protein-based solutions to manage surgical bleeding. Also, in September 2018, Grifols launched GamaSTAN immune globulin (human) for hepatitis A virus (HAV) and measles postexposure prophylaxis, and Prolastin-C Liquid [alpha-1 proteinase inhibitor, liquid] for the treatment of alpha-1 antitrypsin deficiency.
However, the high cost of plasma products, the emergence of recombinant alternatives, and limited reimbursements are some of the factors hindering the growth of the plasma fractionation market during the forecast period.
- coagulation factor concentrates
- protease inhibitors
- Critical Care
- Research Laboratories
North America holds the dominant market share for plasma fractionation in 2018, and it is expected to maintain the growth over the forecast period, owing to the increasing use of immunoglobulins in various applications such as neurological and autoimmune diseases. The growing number of respiratory diseases will increase the adoption of coagulation factors, which in turn will drive the market for plasma fractionation in North America. The burden of respiratory diseases is increasing in the United States. According to the National Center for Health Statistics, currently, more than 25 million people in the United States have asthma and approximately 14.8 million adults have been diagnosed with COPD. COPD is the 4th leading cause of death in the United States.
According to the Centers for Disease Control and Prevention (CDC), in 2014, approximately 142,000 individuals died from COPD, and almost as many died from lung cancer (approximately 155,500) in the same year. In nearly 8 out of 10 cases, COPD is caused by exposure to cigarette smoke. Other environmental exposures (such as those in the workplace) may also cause COPD.
There are advancements in processes, improved formulations, and increased production efficiency. Advancement in technology leads to an improved process of plasma manufacturing, hence leading to the growth of the market in this region. There are many clinics across the region for targeted gene therapies with new advancements in treatments related to cardiovascular diseases, cancer immunotherapies, and blood-related disorders. Several innovations in manufacturing processes (e.g. improvement of yield), product developments (e.g. such as subcutaneous IG, IVIg 10% concentration, and IVIg liquid presentation), presence of advanced virus removal technologies (such as nanofiltration), and the development of newer plasma products such as ceruloplasmin and IgA are also supporting the growth of the plasma fractionation market in these regions. For instance, in August 2016, Shire, announced the U.S. launch of VONVENDI [von Willebrand factor (Recombinant)], the only recombinant treatment for adults living with von Willebrand disease (VWD). The treatment is also the first in the United States that has the option to dose recombinant von Willebrand factor (rVWF) independent of recombinant Factor VIII (rFVIII), based on patient need. This attribute allows for tailored treatment for patients who may not require additional FVIII.
The Plasma Fractionation market is dominated by a few major players including CSL, Grifols, China Biologic Products, Shire (Takeda Pharmaceutical Company), Octapharma Plasma, Inc., Kedrion S.p.A, Sanquin, and LFB SA. The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations which are contributing to the growth of the Plasma Fractionation market globally. For instance,
In June 2019, Grifols, one of the world’s three top providers of plasma-derived medicines to treat life-threatening diseases, launched the VISTASEAL fibrin sealant with Ethicon Inc. as part of a broad global relationship to provide plasma-protein-based solutions to manage surgical bleeding.
In March 2019, Grifols acquired $1.9 billion stakes in Shanghai RAAS Blood Products Co., gaining a major foothold in China’s booming blood-products market.
In January 2019, Takeda Pharmaceutical Company Limited (Japan), a global biopharmaceutical company acquired the Shire, increasing its geographic footprint and global customer base.
In September 2018, Grifols launched GamaSTAN immune globulin (human) for hepatitis A virus (HAV) and measles postexposure prophylaxis, and Prolastin-C Liquid [alpha-1 proteinase inhibitor, liquid] for the treatment of alpha-1 antitrypsin deficiency.
In September 2018, Octapharma invested USD 25 million (Euro 21 million) in a new multi-function facility in Springe, Germany, that will have a new production line for human normal immunoglobulin panzyga, alongside human albumi and albunorm.
In August 2018, Grifols acquired Biotest US Corporation, a subsidiary of Biotest (Germany), to expand its plasma collection network with the addition of 24 Biotest centers in the US.
In February 2018, Guizhou Taibang Biological Products Co. Ltd., a wholly-owned subsidiary of China iologic Products Organization, received approval from the Hainan Provincial Health and Family Planning Commission to build a new plasma collection station in Hainan Province.